The survey aimed at evaluating the quality of selected antimalarials in six countries of sub-Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria and the United Republic of Tanzania). These countries have been supported by WHO to strengthen their regulatory controls o...ver antimalarial products. The survey was organized independently of manufacturers of antimalarial medicines.
more
The Minimum Standards for Age and Disability Inclusion in Humanitarian Action inform the design, implementation, monitoring and evaluation of humanitarian programmes across all sectors and phases of response, and in all emergency contexts, ensuring older people and people with disabilities are not e...xcluded.
more
In this review, the editors will investigate the impact of eight WASH interventions in preventing (reducing the risk of) and controlling outbreaks in LMIC, with particular focus on three diseases of current concern to the response community – cholera, Ebola, and Hepatitis E. Additionally, we will ...explore economic outcomes related to WASH interventions within an outbreak
more
Les Standards Minimums de la Protection de l’Enfant (SMPE) définis en 2012 par le GTPE présentent 26 normes nécessaires pour assurer une protection adéquate des enfants dans les situations d’urgence.
Insecurity Insight Report 13-1.
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011
Primary care - Putting people first: This chapter describes how primary care brings promotion and prevention, cure and care together in a safe, effective and socially productive way at the interface between the population and the health system.
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ...ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
more